Get the Stockscreener App
3.67
2.78%
-0.105
After Hours:
3.67
Lantern Pharma Inc stock is traded at $3.67, with a volume of 31,231.
It is down -2.78% in the last 24 hours and down -10.27% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.775
Open:
$3.74
24h Volume:
31,231
Relative Volume:
0.61
Market Cap:
$39.40M
Revenue:
-
Net Income/Loss:
$-15.16M
P/E Ratio:
-2.7774
EPS:
-1.3214
Net Cash Flow:
$-13.65M
1W Performance:
-7.09%
1M Performance:
-10.27%
6M Performance:
-58.30%
1Y Performance:
+7.62%
1-Day Range:
$3.5491
$3.89
1-Week Range:
$3.5491
$4.14
52-Week Range:
$2.38
$11.99
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma secures three new FDA rare disease tags - Investing.com
Lantern Pharma secures three new FDA rare disease tags - Investing.com India
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - Business Wire
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com
Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World
LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com
LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World
LTRN: Second Quarter Results - Yahoo Finance
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - Business Wire
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire
Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Yahoo Finance
LTRN: Harmonic Clinical Update - Zacks Small Cap Research
LTRN: Harmonic Clinical Update - Yahoo Finance
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Chronicle-Tribune
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - StockTitan
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Business Wire
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - Business Wire
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - StockTitan
Head-To-Head Analysis: Lantern Pharma (NASDAQ:LTRN) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - American Banking and Market News
CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - Defense World
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Marketscreener.com
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate - Yahoo Finance
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Cosmos Health completes hydrogel development for weight management By Investing.com - Investing.com India
Netflix shares price target lifted on Q2 earnings report - Investing.com
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Business Wire
LP-184 synergizes with PARP inhibitor in atypical teratoid rhabdoid tumor - BioWorld Online
How AI is transforming drug discovery - The Pharmaceutical Journal
Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Down 20.6% in June - MarketBeat
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail
Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology ... - The Globe and Mail
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical ... - Quantisnow
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail
Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 - The Globe and Mail
Lantern Pharma Inc (LTRN-Q) QuotePress Release - The Globe and Mail
, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors - Frontiers
Ratios in Focus: Analyzing Lantern Pharma Inc (LTRN)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
H.C. Wainwright initates Lantern Pharma Inc (LTRN) rating to a Buy – Knox Daily - Knox Daily
(LTRN) Trading Signals - Stock Traders Daily
How Much Are Lantern Pharma Inc. (NASDAQ:LTRN) Insiders Spending On Buying Shares? - Yahoo New Zealand News
Lantern Pharma secures Japan patent for cancer drug By Investing.com - Investing.com Australia
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Kreis Leslie W. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Kreis Leslie W. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Kreis Leslie W. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Fletcher Aaron G.L. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Kreis Leslie W. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Fletcher Aaron G.L. | 10% Owner |
Nov 29 '23 |
Sale |
3.44 |
145,348 |
499,997 |
217,553 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):